You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Emtricitabine And Tenofovir Disoproxil Fumarate, and when can generic versions of Emtricitabine And Tenofovir Disoproxil Fumarate launch?

Emtricitabine And Tenofovir Disoproxil Fumarate is a drug marketed by Amneal Pharms Co, Apotex, Aurobindo Pharma, Aurobindo Pharma Ltd, Chartwell Rx, Cipla, Laurus, Macleods Pharms Ltd, Mylan, Strides Pharma, Teva Pharms Usa, and Zydus Pharms. and is included in twelve NDAs.

The generic ingredient in EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is emtricitabine; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Emtricitabine And Tenofovir Disoproxil Fumarate

A generic version of EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE was approved as emtricitabine; tenofovir disoproxil fumarate by TEVA PHARMS USA on June 8th, 2017.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE?
  • What are the global sales for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE?
  • What is Average Wholesale Price for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE?
Summary for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Drug patent expirations by year for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Recent Clinical Trials for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assistance Publique - Hôpitaux de ParisPhase 3
University College, LondonPhase 3
King's College LondonPhase 3

See all EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE clinical trials

US Patents and Regulatory Information for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms Co EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 209721-001 Aug 22, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus Pharms EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 212689-003 Jul 1, 2021 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aurobindo Pharma Ltd EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE emtricitabine; tenofovir disoproxil fumarate TABLET;ORAL 211640-001 Mar 9, 2023 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.